While it is crucial to reiterate that this combination has not been studied in formal clinical trials and remains an off-label experimental approach primarily discussed within biohacking and peptide research communities, the scientific rationale is intriguing
A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (a 20% relative reductions in the semiglutide group)
In particular, lack of early response appears to be strongly indicative of subsequent nonresponse [2], failure to achieve remission [3], and higher rates of treatment discontinuation [4]
While therapeutic targeting of the glucagon pathway holds promise, clinical challenges such as dyslipidemia, hepatic stress, and amino acid imbalance must be carefully addressed
If no serious pathology is found, and the bleeding is not heavy or persistent, a doctor may allow continued semaglutide use with monitoring
Its the same medication, but Ozempic is specifically indicated for type 2 diabetes, while Wegovy (also Semaglutide) is indicated for weight loss
